Kalaris Therapeutics Inc
KLRS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $108,096 | $49,932 | $32,547 | $45,784 |
| - Cash | $42,387 | $88,426 | $100,965 | $118,289 |
| + Debt | $1,545 | $0 | $0 | $0 |
| Enterprise Value | $67,254 | -$38,494 | -$68,418 | -$72,505 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$11,894 | -$11,350 | -$8,753 | -$18,268 |
| % Margin | – | – | – | – |
| Net Income | -$11,894 | -$11,350 | -$10,196 | -$18,268 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.64 | -0.61 | -2.52 | -3.64 |
| % Growth | -4.9% | 75.8% | 30.8% | – |
| Operating Cash Flow | -$11,333 | -$14,885 | -$7,441 | – |
| Capital Expenditures | -$183 | $0 | $0 | – |
| Free Cash Flow | -$11,516 | -$14,885 | -$7,441 | – |